Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-24-016883
Filing Date
2024-04-29
Accepted
2024-04-29 13:10:56
Documents
15
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 form10ka.htm   iXBRL 10-K/A 304017
2 ex31-3.htm EX-31.3 6373
3 ex31-4.htm EX-31.4 6261
  Complete submission text file 0001493152-24-016883.txt   567008

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE pvct-20231231.xsd EX-101.SCH 3027
5 XBRL LABEL FILE pvct-20231231_lab.xml EX-101.LAB 36884
6 XBRL PRESENTATION FILE pvct-20231231_pre.xml EX-101.PRE 24154
18 EXTRACTED XBRL INSTANCE DOCUMENT form10ka_htm.xml XML 6627
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36457 | Film No.: 24889029
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)